MDLN vs. PHG: Medline vs. Koninklijke Philips Stock Comparison

Company Profile

Medline (MDLN) and Koninklijke Philips (PHG) both belong to the Health Care Equipment & Supplies industry, though MDLN is classified under Health Care Supplies while PHG falls under Health Care Equipment.

Koninklijke Philips (PHG) has been public since March 17, 1980, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Medline (MDLN) trades as ordinary local shares, while Koninklijke Philips (PHG) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Koninklijke Philips (PHG) has a non-negative beta of 0.65.

Risk-Adjusted Performance

Risk-Return Positioning

Both MDLN and PHG need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Medline (MDLN) at 4.85% and Koninklijke Philips (PHG) at 8.61% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Medline (MDLN) at 1.85% and Koninklijke Philips (PHG) at 5.39% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Medline (MDLN) at 5.22% and Koninklijke Philips (PHG) at 3.76% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Koninklijke Philips (PHG) reports revenue growth of -1.04%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Only one side can be read here: Medline (MDLN) reports EPS growth of 117.38%, ranked against its industry; Koninklijke Philips (PHG) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Medline (MDLN) at 4.04 carries current ratio above its industry’s typical mid-range, while Koninklijke Philips (PHG) at 1.33 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Medline (MDLN) at 0.65 and Koninklijke Philips (PHG) at 0.70 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Medline (MDLN) nor Koninklijke Philips (PHG) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Koninklijke Philips (PHG) reports payout ratio above 100% at 211.79%, meaning dividends exceeded current-period earnings; Medline (MDLN) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Koninklijke Philips (PHG) at 63.23 sits in the richer P/E ratio quartile, and Medline (MDLN) at 90.09 is richer still, above its industry range.

On P/S ratio, both Medline (MDLN) at 1.70 and Koninklijke Philips (PHG) at 1.67 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Medline (MDLN) at 2.95 and Koninklijke Philips (PHG) at 2.28 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics